Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparPiPPa: Inavolisib in Neoadjuvant Treatment of Early Breast Cancer
NCT05306041Phase 2Recruiting
- Sponsor
- GBG Forschungs
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of inavolisib in breast cancer, sponsored by GBG Forschungs. Started Jan 2023; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05306041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306041.